Avita Medical Ltd. Patent Validated in Eleven European Countries
Marketwired - Wed Sep 02, 5:00AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that one of its European patents has been validated in Austria, Belgium, France, Germany, Great Britain, Italy, the Netherlands, Portugal, Spain, Sweden and Turkey.
AVH: 5.54 (-0.15)
Avita Medical Announces New Research Partnership With University of Huddersfield
Marketwired - Mon Aug 17, 5:00AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has forged a partnership with England's University of Huddersfield to explore the mechanism of Regenerative Epithelial Suspension (RES(TM)) -- from Avita's ReCell(R) device -- to better understand its ability to effectively treat burns, hard-to-heal wounds and skin trauma.
AVH: 5.54 (-0.15)
Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year 2015
Marketwired - Wed Jul 29, 3:09PM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced its financial results and provided a corporate update for the fourth quarter and twelve months ended June 30, 2015.
AVH: 5.54 (-0.15)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 6.36 (+0.01), SNN: 36.15 (-0.15), JNJ: 92.93 (+0.21), MMM: 141.26 (+0.48), OSIR: 19.32 (+0.52), MDXG: 10.12 (-0.15), NVDQ: 11.93 (-0.06)
Avita Medical's ReCell(R) Recognized as Innovative Treatment for Burn Victims
Marketwired - Mon Jul 20, 7:00AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today said a branch of the U.S. Military says the U.S. Department of Defense 'wants to use' the company's ReCell(R) technology, which it described as offering a possible 'paradigm shift' in skin injury treatment.
AVH: 5.54 (-0.15)
Avita Medical Sends Devices and Personnel to Help Treat Mass Burn Victims in Taiwan
Marketwired - Tue Jul 07, 7:30AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, has donated a number of free ReCell(R) devices and sent personnel experienced in burn treatment to provide any support requested by authorities in Taiwan, where hundreds of people have been left seriously burned in a mass casualty event at a waterpark.
AVH: 5.54 (-0.15)
Avita Medical Data Demonstrating ReCell(R) Effectiveness in Skin Repigmentation Published in Journal of the American Academy of Dermatology
Marketwired - Mon Jul 06, 7:30AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that statistically significant data from a randomized controlled study demonstrated that its single-use autologous cell suspension technology ReCell(R) was safe and effective in skin repigmentation for patients suffering with depigmented skin lesions caused by vitiligo and piebaldism. Results of the study have been published online and in the July 2015 print issue of the Journal of the American Academy of Dermatology,1 the official publication of the American Academy of Dermatology (AAD).
AVH: 5.54 (-0.15)
Avita Medical Announces Notice of Allowance of 2nd U.S. Patent Application
Marketwired - Wed Jun 17, 5:00AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/223,577. The allowed application is directed to the novel composition of matter in the form of an epithelial cell suspension, in connection with the Company's proprietary platform of regenerative products (ReCell(R), ReNovaCell(TM) and ReGenerCell(TM)).
AVH: 5.54 (-0.15)
Avita Medical: Why This Tiny Medical Device Player Is Positioned For A Turnaround
Jason Napodano, CFA - at Seeking Alpha - Wed Jun 03, 8:34AM CDT
Avita Medical's ReCell Featured at Important US Government Symposium on Emergency Preparedness
Marketwired - Thu May 21, 5:00AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the company participated, by invitation, in a key US Government Symposium focused on Emergency Preparedness. The presentation to influential delegates addressed how the ReCell(R) medical device could be a versatile and effective treatment for burns and skin wounds in a mass casualty event.
AVH: 5.54 (-0.15)
Avita Medical Announces Issuance of a New U.S. Patent for ReCell(R)
Marketwired - Wed May 13, 5:01AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,029,140. The patent is directed to methods of making and using an epithelial cell suspension, part of the Company's novel autologous skin regeneration therapy platform (ReCell(R)).
AVH: 5.54 (-0.15)
Avita Medical Granted CE Mark for Expanded ReCell(TM)
Marketwired - Mon Apr 27, 4:30AM CDT
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that it has received a CE Mark for a new ReCell device for the treatment of burns. This enhanced ReCell product offers treatment of up to a 1,920cm2 surface area; a 6-fold greater coverage than previously possible from the first generation product. The original ReCell device, covering 320cm2, allowed clinicians to treat only approximately 1.5% of an adult's total body surface area (TBSA). With the new device, ReCell is better aligned to meet grafting requirements of burn victims.
AVH: 5.54 (-0.15)
Avita Hosts International Skin Regeneration Symposium Attended by Leading Clinicians
Marketwired - Thu Apr 23, 4:30AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today provided a summary of its Skin Regeneration Symposium which was held on April 14th - 15th at Cambridge University. The forum, which was attended by more than 80 clinicians from around the world, featured keynote speakers; presentations and panel discussions all focused on using regenerative medicine to treat burns, wound care, trauma, aesthetic revision and plastics reconstruction. A key outcome from the symposium was the conclusion that a novel epithelial suspension used to regenerate skin for patients suffering from burns and chronic wounds can be a vital part of a surgeon's toolkit, and results can be further optimised when ReCell is used with other standard medical devices.
AVH: 5.54 (-0.15)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.40 (-0.06), GBSNU: 16.22 (-0.28), MZOR: 11.44 (-0.41), FEIC: 75.95 (+0.76), ZLTQ: 35.24 (+0.36), IART: 64.10 (+0.90), BVX: 2.38 (+0.03)
Avita Medical Appoints Adam Kelliher as Chief Executive Officer
Marketwired - Tue Apr 14, 4:30AM CDT
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the appointment of Mr. Adam Kelliher as Chief Executive Officer. Tim Rooney, who has been serving as Interim Chief Executive Officer, will resume his role as the Company's Chief Financial Officer and Chief Operating Officer.
AVH: 5.54 (-0.15)
Avita Medical Announces First Patient Enrollment in US Pivotal Study of ReCell(R) for the Treatment of Burns
Marketwired - Wed Jan 28, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company's Pivotal Phase III burn trial for ReCell(R).
AVH: 5.54 (-0.15)
UPDATE - Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 4:04PM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted.
AVH: 5.54 (-0.15)
Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 12:10PM CST
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted. The Company is continuing collaboration with the Medical Technologies Evaluation Programme at NICE toward further development of the evidence base.
AVH: 5.54 (-0.15)
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive
Marketwired - Tue Nov 11, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of $1.4M for the financial year ending 30 June 2014.
AVH: 5.54 (-0.15)
Avita Medical Secures US FDA Approval to Modify ReCell(R) Clinical Burns Trial
Marketwire - Tue Sep 16, 11:25AM CDT
Highlights
AVH: 5.54 (-0.15)